# Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

> **NCT03135249** · PHASE4 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 9 (actual)

## Conditions studied

- Multiple Sclerosis (MS)

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT03135249
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2020-11-04
- **Final completion:** 2020-11-04
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03135249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03135249, "Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03135249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*